Podcast episode 129 (in German)
Dasatinib plus quercetin – the zombie cell cure, a mechanism and a placebo
November 6, 2026
Dasatinib plus quercetin is supposed to clear aging zombie cells out of the body, and in human tissue samples it actually succeeds. The episode shows why the combination is still not a finished tool — and what remains instead with data in humans.
What it is about
Aging cells that no longer divide and yet do not die remain in tissue and release inflammatory substances; technically they are called senescent cells. The idea behind senolytics is one of the most beautiful in aging research: you do not have to repair these cells, only get rid of them. Dasatinib, an approved leukemia drug, and the plant compound quercetin block different emergency exits these cells use to survive, and are therefore given only on a few days, following the hit-and-run principle. The episode goes through the data from the mouse experiment via the biopsy study to the randomized bone study, and looks at 19 volunteers from a hormone practice who took the protocol for 6 months; 10 of them came back for a second round. At the end stands a friendly, clear verdict: the idea holds, the tool is not finished yet.
Key points
- In 9 people with diabetic kidney disease, 11 days after 3 days of the combination, adipose tissue showed 35 percent fewer cells with the most important senescence marker, and 62 percent fewer for the second marker.
- In an open-label study of 14 people with pulmonary fibrosis, participants walked further and faster afterwards; in the blinded repetition with placebo in 12 people, physical function did not differ meaningfully.
- The largest study, 60 postmenopausal women over 20 weeks, missed its primary goal: minus 4.1 versus minus 7.7 percent in the bone resorption marker, with a p-value of 0.61.
- Only in the women with the highest senescence burden did a bone formation marker rise by 34 percent, and bone density in the forearm was 2.7 percent higher — explicitly described by the authors as exploratory.
- In the placebo-controlled lung study, 65 non-serious adverse events occurred on the combination and 22 on placebo; sleep disturbances and anxiety in 4 of 6 treated people, in 0 of 6 on placebo.
- In the 19 volunteers, the older epigenetic clocks showed faster rather than slower aging after 3 and after 6 months, the newer clocks no difference — without a control group, so it cannot be attributed.
Where the data stop
The mechanism has been shown in humans, in tissue samples before and after, albeit without a control group. With the benefit, a pattern emerges: every time a placebo stood alongside, it became smaller or disappeared. The reading that the wrong people were simply treated is logical; however, a study that sorts by senescence burden in advance was not found in the registry. In the cerebrospinal fluid, dasatinib arrived in 4 of 5 people with early Alzheimer’s disease, at less than 1 percent of the blood level, quercetin not at all; according to the registry, a follow-up study with 48 people is due to be completed in 2028.
There is no safety database for pulsed use, and dasatinib is prescription-only and approved only for certain leukemias, not for aging. Anyone who sleeps poorly after the pulse days is not imagining it; the prescribing information lists insomnia as common. What remains with data in humans is exercise: 12 weeks of training lowered exactly these senescence markers in the blood of older people, and the participants said they moved better.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on November 6, 2026.
The topic in the database
- The classic “zombie cell cure” of longevity research: clears senescent cells from tissue in pulses – only a few days a month.Dasatinib + Quercetin (senolytic stack)
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.